Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment reporting

Analytics

Phase 2

4(50.0%)

Phase 3

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 2(4)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05489887Phase 2Recruiting

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Role: lead

NCT05394142Phase 2Unknown

A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)

Role: lead

SYF0b61f3c064bb45cfab001a0100d8ee56Phase 3Not Yet Recruiting

Clinical trial to evaluate whether sildenafil citrate can reduce adverse effects during childbirth in small fetuses

Role: lead

SYF82810fd707a3497fa61280a6ad1624d4Phase 1Recruiting

Early phase clinical trial to evaluate the safety of the combination of immunotherapy with dendritic cells pulsed and tumor lysate, together with CAR-T cells targeting IL13Ra2, in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)

Role: lead

SYF8601717afe3d4b12acdf2916e56cf6a4Phase 2Unknown

Investigating a New Treatment: Clinical Study on Coenzyme Q (Ubiquinol) for Patients with Mitochondrial Disorders and Cerebellar Ataxias

Role: lead

SYFb382d2df2ce94ead98e170eeccd9a662Phase 2Active Not Recruiting

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in children and adolescents aged 0-18 years with CD19+ acute lymphoblastic leukaemia resistant or refractory to treatment.

Role: lead

SYFecb34d1773c0466b836721876bf33e52Phase 3Recruiting

Study to evaluate the efficacy and safety of enoxaparin in children with slow-flow vascular problems undergoing interventional procedures

Role: lead

SYFfb85acc402c04f7d8064420546d82b51Phase 3Recruiting

Improving Heart Scans in Children: A Study Comparing Two Contrast Agents for MRI

Role: lead

All 8 trials loaded